高毒力多重耐药ST147肺炎克雷伯菌在重症COVID-19患者中的传播:意大利2020-21年观察性研究
在意大利比萨大学医院开展前瞻性观察性研究,纳入连续收治的COVID-19合并高毒力肺炎克雷伯菌(hvKp)感染患者。2020年11月至2021年3月共分离出36株hvKp,均为ST147型、产ESBL,仅对美罗培南和头孢他啶/阿维巴坦敏感。29例感染者30天死亡率为48.3%(14/29)。
要点
- hvKp分离株均属ST147,产ESBL,仅对美罗培南和头孢他啶/阿维巴坦敏感。
- 36例中29例(80.6%)为感染,7例(19.4%)为定植。
- 感染者30天死亡率为48.3%(14/29)。
核心结论
- 产ESBL的ST147高毒力肺炎克雷伯菌与COVID-19患者高死亡率相关。
- 该人群需要严格的微生物学监测和感染控制措施。
研究设计与样本
- 前瞻性观察性研究,纳入意大利比萨大学医院连续收治的COVID-19合并hvKp感染患者。
- 收集患者临床数据及结局,所有患者随访至感染诊断后30天。
- 对暴发不同时期采集的3株菌进行分子分型及全基因组测序。
主要发现
- 2020年11月至2021年3月,从36例COVID-19患者中分离出hvKp。
- 29/36(80.6%)为感染:15例血流感染、8例呼吸机相关性肺炎、6例复杂性尿路感染。
- 7/36(19.4%)为定植:3例尿液、2例直肠、2例皮肤。
- 分离株属ST147,质粒携带IncFIB(Mar)、IncR和IncHI1B三种复制子及包括rmpADC在内的多个耐药基因。
- hvKp分离株呈ESBL表型,对哌拉西林/他唑巴坦和头孢他啶/阿维巴坦耐药,仅对美罗培南和头孢他啶/阿维巴坦敏感。
临床怎么用
- 作者认为,该人群需要严格的微生物学监测和感染控制措施。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To report an outbreak of hypervirulent Klebsiella pneumoniae (hvKp) in COVID-19 patients. METHODS: Prospective, observational study including consecutive COVID-19 patients with hvKp infections admitted to the University Hospital of Pisa (Italy). Clinical data and outcome of patients were collected. All patients were followed-up to 30 days from the diagnosis of infection. Mortality within 30 days of the diagnosis of hvKp infection was reported. The hypermucoviscous phenotype was determined by the 'string test'. Molecular typing was performed on three strains collected during different periods of the outbreak. The strains underwent whole genome sequencing using the Illumina MiSeq instrument. The complete circular assemblies were also obtained for the chromosome and a large plasmid using the Unicycler tool. RESULTS: From November 2020 to March 2021, hvKp has been isolated from 36 COVID-19 patients: 29/36 (80.6%) had infections (15 bloodstream infections, 8 ventilator-associated pneumonias and 6 complicated urinary tract infections), while 7/36 (19.4%) had colonization (3 urine, 2 rectal and 2 skin). The isolates belonged to ST147 and their plasmid carried three replicons of the IncFIB (Mar), IncR and IncHI1B types and several resistance genes, including the rmpADC genes encoding enhancers of capsular synthesis. The hvKp isolates displayed an ESBL phenotype, with resistance to piperacillin/tazobactam and ceftolozane/tazobactam and susceptibility only to meropenem and ceftazidime/avibactam. The majority of patients were treated with meropenem alone or in combination with fosfomycin. Thirty-day mortality was 48.3% (14/29). CONCLUSIONS: ST147 ESBL-producing hvKp is associated with high mortality in COVID-19 patients. Strict microbiological surveillance and infection control measures are needed in this population.
引用
- Falcone M, Tiseo G, Arcari G, et al. Spread of hypervirulent multidrug-resistant ST147 Klebsiella pneumoniae in patients with severe COVID-19: an observational study from Italy, 2020-21. J Antimicrob Chemother. 2022. PMID: 35040981. doi:10.1093/jac/dkab495
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。